Alertgy NICBGM Sets *ALL* Diabetics Free

DeepGluco®

Fully Non-Invasive Continuous *Blood* Glucose Monitor (NIBCGM)

Alertgy

Improving Diabetic Health Through Innovation

Diabetes: Growing Global Problem

2018 Estimates

Target Market



Target Market





https://diabetesatlas.org/en/resources/ |https://diabetesatlas.org/upload/resources/previous/files/8/IDF_DA_8e-EN-final.pdf |2014 Source, CDC; http://http://www.cdc.gov/diabetes/statistics/prev/national/figpersons.html

Economic & Human Cost of Diabetes

Diagnosed Diabetes

Growing US Population 1985 - 2018





Alertgy

Improving Diabetic Health Through Innovation

DeepGluco® Solution

The first wearable Non-Invasive Continuous Blood Glucose Monitoring and Alert system (NICBGM)



- The first wearable NICBGM
- IoT cloud-based analytics
- Incorporates IoT based advanced AI
- Automated Alerts and Data logging
- Fully reimbursable digital health solution

Technology of DeepGluco®

- **Dielectric Spectroscopy** measures blood glucose directly
- **Advanced Dielectric Materials** used to provide wide band sensitivity and selectivity
- **Cloud-based AI Analytics** provides alerts, data logging and optimal performance
- **Protected by patents, licenses, & trade secrets**





Human Forearm

Alertgy Data: glucose level analytic range demonstrated from 40 – 400 mg/dL

Serviceable Addressable Market

Alertgy

Strong unmet need exists for easy-to-use non-invasive monitor and worldwide alert system that can address the needs of ***ALL*** Diabetics and those who are borderline.

Diabetes is a long-term medical condition in which your body does not use insulin properly, resulting in unusual blood sugar levels

- 420 million Diagnosed Diabetics in the World
- 120 million undiagnosed Diabetics in the World
- 1/3 of Worlds Population or 2 billion are pre-diabetic

- 90% unaware ofcondition
- 30% pre-diabetics are expected to develop type 2 diabetes within 5 years
- Type 2 often diagnosed several years after onset
- WHO estimates that diabetes was the seventh leading cause of death in 2016

DeepGluco®: At the Intersection of IoT, AI, Wearables & Digital Health

DeepGluco™ addresses a broad unmet need / market opportunity:

- Drives diabetic type 2 compliance, and discovers diabetes early reducing costs and saving lives.
- Enables borderline diabetic awareness.
- 2020 Healthcare IoT market size is $50.3 B, predicted to reach $136 B in 2025.
- 31 billion IoT devices worldwide in 2020, with 75 billion projected by 2025.
- Digital health fully reimbursable with today's codes

Healthcare IoT Market Size: 2016-2025

Market Forecast (in B$)



Projected size of the Internet of Things (IoT) in healthcare market worldwide from 2016 to 2025 (in billion U.S. dollars)

Business Model

Three Sources of Revenue from Partners:

- Licensing fees
- Royalties on product sales
- Dielectric Materials for Sensor

Subscription Model:

- $30 subscription model IoT Analytics, logging, reporting
- Monthly fee per device



Revenue & Profitability Projections



Key Considerations

- Untapped Type 2 Diabetes Market Potential
- Robust Clinical Evidence
- Unique IoT Cloud & AI platform
- Established IP/Trade Secrets
- Corporate Interest
- Experienced Leadership

Revenue CAGR of 395.4% over four years and Operating Profit of $123 Million and $211 Million in years 3 and 4, respectively

Product Status

Wearable DeepGluco®

Smart Phone DeepGluco® Apps

IoT Platform AI Powered Analytics

Accurate Glucose Readings

End-User Experience

- » Easy to use
- » Fully automated alerts
- » On demand reading
- » Secondary alerts to others
- » Compliance alerts
- » Automated data logging
- » Continual automated optimization of AI
- » Reimbursable data driven digital health
- » Options for reporting

= Operational Demonstrated Fully Scalable

DeepGluco® NICBGM Versus CGM

Fully Non-Invasive Continuous *Blood* Glucose Monitor (NIBCGM)

CompleteCare Family Medicine

**Alertgy Data collected In Vivo 27 Patient Clinical Trials by 3rd Party Medical Clinic

Analytical Range 40 – 400 ug/dl

	Dexcom (G5)	Abbott (Libre Pro)	Senseonics (Eversense)	Alertgy
Invasiveness & Sensor Placement	Skin Pierce on Abdomen	Skin Pierce on Upper Arm	Surgically Implanted Upper Arm	Non-Invasive On Wrist
Measurand	Glucose in Intestitial Fluid	Glucose in Intestitial Fluid	Glucose in Intestitial Fluid	Glucose in Blood
MARD (%)	16.3*	18.0*	15.1*	15.3
Sensor Lifetime (days)	10	14	90	>Year
Cost per Day in $ US Dollars	20	10	>10	< 2

*MARD values source for Dexcom (G5), Abbott (Libre Pro), Senseonics (Eversense): https://diabetes.diabetesjournals.org/content/67/Supplement_1/14-OR

Alertgy Traction



Executive Team

Experience & Successful Team of **Clinicians, Technologist & Entrepreneurs** (See website for detailed bios)

Marc Rippen
CEO

Rob Strandberg
CFO

Alex Radetich
Chief Business Development Officer

Helga Rippen
MD, PhD, MPH
Chief Medical Officer

John Hodges
CTO

Key Team **Members & Advisors** (See website for detailed bios)

Dr. John Burd
Investor / Board Member
Founder, Dexcom

John Hubert
VP of Engineering

Craig Nelson
VP of Manufacturing

Ben Freer
Principal Sensor Engineer

Kent J. Lyon, MD
Clinical Advisor
Endocrinologist

Competitive Landscape

Real Time Vascular Glucose

Invasive

Non-Invasive

Lag Interstitial Glucose

Roche

YSI

ACCU-CHEK®

Alertgy

Dexcom

Medtronic

glucowise

movano

echo THERAPEUTICS

Abbott

Helo extense

C8 MediSensors™

KNOW LABS INC

Competition RF CGM

Alertgy
Improving Diabetic Health Through Innovation

Alertgy is Clearly Ahead of RF based Competition

	Alertgy	Movano	Know Labs
Wristband Product Developed?	YES	NO	YES
3rd Party Clinical Trials	YES (2)	NO	NO
Capable of wideband 50-500 MHZ	YES	NO	NO
Patented	YES	YES	YES
Detects Blood Glucose	YES	NO	NO
RF Interferences	NO	YES	YES

Investment Summary

- Alertgy provides clinical non-invasive solution
- Other CGMs can only measure a patient's interstitial fluid glucose levels and NOT venular or arteriole (blood) glucose
- Interstitial glucose can lag blood glucose readings by up to 30 minutes

- Alertgy graduated in the first cohort of ten companies in the Cleveland Clinic (CC) Plug and Play venture health technology accelerator program.
- Won the Health Innovators Diabetes Challenge Pitch, sponsors include Blue Cross Blue Shield and Ochsner Health.

Investment Environment

Fitbit
raised over $1.01 Billion
Acquired by Google

Dexcom
raised over $327 Million
Valued at 40 Billion (2/2021)

Movano
raised over $50 Million
Valued at $171 Million

Insulet
raised over $500 Million
Valued at $223/Share (9/2020)

Intuity Medical
raised over $46 Million & $75 Million
Valued at $95.2 Million

Future Applications

The same Alertgy device with modified settings and software could be used to detect and quantify many highly specific proteins and biomarkers. Although the Company is currently focusing 100% of its efforts on serving the diabetes market, other potential applications are listed below.

- Cancer, heart disease, through protein markers in Blood
- COVID-19 and Human Respiratory Syncytial Virus (RSV) detection
- Adenovirus type 5 (AV 5), Herpes Simplex Virus type 1(HSV1), Simian Virus 40 (SV40), Vaccinia (MVA), and Cowpea Mosaic Virus (CPMV)
- Radiation sickness early detection (NASA for Mars Mission)
- Monitor bone density and muscle loss & body fluid shifts (NASA for Mars Mission)
- Human and Feline Immunodeficiency Viruses (HIV and FIV)
- Mad Cow Diseases (vCJD, sCJD, non-CJD)

Funding Objective

Alertgy already RAISED $3,500,000

in Seed and Bridge capital

Next steps: SEEKING

$10,000,000

Uses of Funds:

- **DeepGluco® FDA trials**
- **Development of Custom Chip**
- **Additional engineering hires**
- **Intellectual property/legal**

Contact: Marc Rippen, CEO

marc@alertgy.com

727 455-9076

Projected Milestones



DeepGluco® Clinical FDA Approval

REGULATORY

FDA Class 2 | DeNovo Device Approval Process

Pre-Submission
(3 Months before testing)

- Ensure testing approach meets PMA / DeNovo requirements
- Keep FDA abreast of progress, introduce new tech & support timeline

Data Collection / Clinical Trials (3-9 Months)

- Data collection for approval process
- Completion of submission material

Review Process & Approval
(3-5 Months)

Summary DeepGluco®

Alertgy® has developed a wearable medical device known as **DeepGluco®**, a truly Non-Invasive Continuous Blood Glucose Monitor (NICBGM®), and alert system needed by diabetics for real-time blood glucose measurement.

Using dielectric spectroscopy, the Company can successfully sync the data gained by the wristband's dielectric sensor to a smartphone enabled application, using internet of things (IOT) cloud-based analytics. Alertgy uses this data to develop a personalized historical spectrum of historical data for each individual patient, which represents the Company's core business.

Market/Competitive Advantage

- Alertgy offers a fully non-invasive CGM with multiyear sensor life
- No interstitial lag time
- Alertgy's technology can be used to analyze other medical conditions
- Focus on underserved Diabetic markets (95% of the overall diabetic market)
- World class management and advisory teams.

Commercial Positioning

- Successfully completed two 3rd party clinical trials with DeepGluco® technology
- Full US patent issued
- Commercial product developed
- FDA approval process initiated Q1 2021
- Collaborative Research Agreement for Custom Chip development with IMEC

Alertgy Products

Alertgy
Improving Diabetic Health Through Innovation

Clinical



Wristband



Alertgy
Improving Diabetic Health Through Innovation

DeepGluco® ASIC Product





- **Research Collaborative Agreement in Place with IMEC for spectrometer on a Chip**
- **Lower cost to manufacture**
- **10x more battery life**
- **Smaller**
- **ASIC chip IP**